<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441584</url>
  </required_header>
  <id_info>
    <org_study_id>P03833</org_study_id>
    <secondary_id>ESPECIAL</secondary_id>
    <nct_id>NCT00441584</nct_id>
  </id_info>
  <brief_title>The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)</brief_title>
  <official_title>Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Therapeutics Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate&#xD;
      the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C. The&#xD;
      study is designed to determine the proportion of chronic hepatitis C genotype 1 subjects who&#xD;
      did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve&#xD;
      sustained virological response (SVR) when treated with PegIntron plus Rebetol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Subject accrual was prematurely terminated due slow enrollment.&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</measure>
    <time_frame>Up to 48 weeks of treatment plus 24 weeks follow up</time_frame>
    <description>Sustained virologic response is defined as a plasma HCV RNA level below Lower Level of Quantitation at 24 weeks post-treatment, which is &lt; 30 IU/mL in this study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b)</intervention_name>
    <description>Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks</description>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <other_name>SCH 54031, PEG-Intron, PegIntron, ViraferonPeg, peginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebetol (ribavirin)</intervention_name>
    <description>200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks</description>
    <arm_group_label>PegIntron plus Rebetol</arm_group_label>
    <other_name>SCH 18908, Rebetol, REBETOL, ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must demonstrate their willingness to participate in the study and comply with&#xD;
             its procedures by signing a written informed consent.&#xD;
&#xD;
          -  Subject must be 18-70 years of age of either sex and of any race.&#xD;
&#xD;
          -  Subject must be diagnosed with chronic hepatitis C genotype 1 (confirmation by biopsy&#xD;
             not required). (Liver function tests (LFTs) can be normal or elevated.)&#xD;
&#xD;
          -  Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal,&#xD;
             surgically sterile or using 2 methods of birth control. While abstinence from sexual&#xD;
             activity is the only certain method to prevent pregnancy, female patients of&#xD;
             childbearing potential who are or who anticipate the possibility of becoming sexually&#xD;
             active with a male partner must use a combination of the following 2 methods:&#xD;
&#xD;
               -  Contraceptive pill or intrauterine device (IUD) or depot hormonal preparation&#xD;
                  (ring, injection, implant), and&#xD;
&#xD;
               -  A barrier method of contraception such as diaphragm, sponge with spermicide,&#xD;
                  condom, or a method of birth control considered acceptable by the study&#xD;
                  physician.&#xD;
&#xD;
          -  Contraceptive measures will be reviewed with female subjects at each visit. Dual&#xD;
             methods of contraception must be used for 6 months after treatment discontinuation.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             screen phase and during the study.&#xD;
&#xD;
          -  Confirmation by the principal investigator or a sub-investigator that sexually active&#xD;
             male subjects are practicing a method of contraception considered acceptable&#xD;
             (vasectomy, condom plus spermicide, plus relationship with a female partner who&#xD;
             practices an acceptable method of contraception). Contraception must be used during&#xD;
             the treatment period and for seven months after the completion of therapy, including&#xD;
             condom use by male subjects with pregnant partners.&#xD;
&#xD;
          -  Subject must be free of any clinically significant disease that would interfere with&#xD;
             study evaluations.&#xD;
&#xD;
          -  Subject must understand, be able to and agree to adhere to the dosing and visit&#xD;
             schedules.&#xD;
&#xD;
          -  Compensated liver disease with the following minimum hematologic and biochemical&#xD;
             criteria at the Day 1 visit within normal limits:&#xD;
&#xD;
               -  Hemoglobin values equal to or greater than 12 g/dL for females and 13 g/dL for&#xD;
                  males&#xD;
&#xD;
               -  White blood cell (WBC) count equal to or greater than 3,000/cu mm&#xD;
&#xD;
               -  Neutrophil count equal to or greater than 1,500/cu mm&#xD;
&#xD;
               -  Platelet count equal to or greater than 80,000/cu mm&#xD;
&#xD;
               -  Direct bilirubin within normal limits&#xD;
&#xD;
               -  Indirect bilirubin within normal limits (unless non-hepatitis related factors&#xD;
                  such as Gilbert's disease explain an indirect bilirubin rise). In such cases&#xD;
                  indirect bilirubin should be less than or equal to 3.0 mg/dL (less than or equal&#xD;
                  to 51.3 µmol/L)&#xD;
&#xD;
               -  Albumin within normal limits&#xD;
&#xD;
               -  Serum creatinine within normal limits&#xD;
&#xD;
               -  Subject must be a non-responder, defined as having received and not having&#xD;
                  responded to a prior treatment consisting of one course of Pegasys 180 mcg QW in&#xD;
                  combination with ribavirin 1000-1200 mg daily, with or without amantadine, for a&#xD;
                  minimum of 12 weeks and:&#xD;
&#xD;
                    -  Subject must be found to be hepatitis C virus (HCV)-ribonucleic acid (RNA)&#xD;
                       positive with less than a 2-log drop at 12 weeks of treatment, or&#xD;
&#xD;
                    -  is polymerase chain reaction (PCR)-positive at End Of Treatment, whether End&#xD;
                       Of Treatment happened at week 48 or earlier&#xD;
&#xD;
          -  Subject must be off Pegasys/ribavirin at least 12 weeks prior to screen.&#xD;
&#xD;
          -  Subject must have had no other treatment with any interferon except Pegasys.&#xD;
&#xD;
          -  Subject must neither have received nor currently be on any other treatment for his&#xD;
             chronic hepatitis C disease, except for amantadine.&#xD;
&#xD;
          -  When available, historical liver biopsy with pathology report of the subject must&#xD;
             confirm that the histological diagnosis is consistent with chronic hepatitis C.&#xD;
&#xD;
          -  Subject must have a value of thyroid stimulating hormone within normal limits (whether&#xD;
             euthyroid or requiring thyroid medications).&#xD;
&#xD;
          -  Antinuclear antibodies must be less than or equal to 1:320.&#xD;
&#xD;
          -  If abdominal imaging has been performed within 1 year prior to screen, it must not&#xD;
             show evidence of focal mass suggestive of hepatoma and/or ascites.&#xD;
&#xD;
          -  For subjects with a history of diabetes or hypertension, clearance from an&#xD;
             ophthalmologist has to be obtained prior to treatment start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is a female who is pregnant or breastfeeding, or who intends to become&#xD;
             pregnant during the study.&#xD;
&#xD;
          -  Subject has used any investigational product within 30 days prior to enrollment or is&#xD;
             currently involved in another clinical trial.&#xD;
&#xD;
          -  Subjects weighing over 125 kg.&#xD;
&#xD;
          -  Subject has any of the following causes for the liver disease based on subject history&#xD;
             or biopsy (where applicable) other than chronic hepatitis C, including but not limited&#xD;
             to:&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Alpha-1 antitrypsin deficiency&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
               -  Autoimmune hepatitis&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Non-alcoholic steatohepatitis (NASH)&#xD;
&#xD;
               -  Drug-related liver disease&#xD;
&#xD;
          -  Subject has any clinically significant deviation from normal in the physical&#xD;
             examination, chest x-ray, or electrocardiogram (ECG) that, in the investigator's&#xD;
             judgment, may interfere with the study evaluation or affect subject safety.&#xD;
&#xD;
          -  Subject is in a situation or condition that, in the opinion of the investigator, may&#xD;
             interfere with optimal participation in the study.&#xD;
&#xD;
          -  Subject is part of the staff or a family member of the staff personnel directly&#xD;
             involved with this study.&#xD;
&#xD;
          -  Subject is a previously untreated subject.&#xD;
&#xD;
          -  Subject has been treated with Pegasys + less than 1000 mg of ribavirin (instead of&#xD;
             with 1000-1200 mg of ribavirin).&#xD;
&#xD;
          -  Subject has been discontinued from Pegasys treatment at any week due to an adverse&#xD;
             event.&#xD;
&#xD;
          -  Subject is co-infected with human immunodeficiency virus (HIV) and/or hepatitis B&#xD;
             virus (HBV).&#xD;
&#xD;
          -  Subject is suspected to be hypersensitive to interferon alpha or Peg-Intron or&#xD;
             ribavirin.&#xD;
&#xD;
          -  Subject has previously received interferon, (except for the Pegasys flat dose 180 mcg&#xD;
             QW for at least 12 weeks), thymosin or Cell Cept treatment or any other drug intended&#xD;
             to treat chronic hepatitis C.&#xD;
&#xD;
          -  Subject has had organ transplants other than cornea and hair transplant.&#xD;
&#xD;
          -  Subject has a history of hepatocellular carcinoma or any other malignancy (except&#xD;
             basal cell carcinoma) within the last 5 years or a suspected diagnosis of&#xD;
             hepatocellular carcinoma or other malignancy, or an active malignancy.&#xD;
&#xD;
          -  Known coagulation diseases such as hemophilia; hemoglobin diseases (e.g. thalassemia).&#xD;
&#xD;
          -  Subject has glucose-6-phosphate dehydrogenase (G6PD) deficiency.&#xD;
&#xD;
          -  Subject has an evidence of decompensated liver disease such as history or presence of&#xD;
             ascites, bleeding varices, spontaneous encephalopathy.&#xD;
&#xD;
          -  Subject has any known pre-existing medical condition that could interfere with the&#xD;
             subject's participation in and completion of the study as followed below:&#xD;
&#xD;
               -  Preexisting psychiatric condition, especially moderate to severe depression, or a&#xD;
                  history of severe psychiatric disorder, such as psychosis, suicidal ideation, or&#xD;
                  suicide attempts. Severe depression includes the following:&#xD;
&#xD;
                    -  Hospitalization for depression&#xD;
&#xD;
                    -  Electroconvulsive therapy for depression, or&#xD;
&#xD;
                    -  Depression causing a prolonged absence from work or significantly altering&#xD;
                       daily functions.&#xD;
&#xD;
          -  Subjects with mild depression may be considered for entry into the study provided that&#xD;
             a pre-treatment assessment demonstrates that the subject's emotional status is&#xD;
             clinically stable, in which case a management plan must be formulated for the subject;&#xD;
             this management plan will become a part of the subject's medical record.&#xD;
&#xD;
               -  Craniocerebral trauma, which is not a concussion, or active seizure disorders&#xD;
                  requiring medication.&#xD;
&#xD;
               -  Clinically significant ECG abnormalities and/or cardiovascular dysfunction within&#xD;
                  6 previous months (e.g., angina, congestive heart failure, recent myocardial&#xD;
                  infarction, or significant arrhythmia).&#xD;
&#xD;
               -  Chronic lung disease (e.g., chronic obstructive lung disease)&#xD;
&#xD;
               -  Poorly controlled diabetes mellitus: HbA1C more than or equal to 8.5%&#xD;
&#xD;
               -  Immune-mediated disease (e.g., inflammatory bowel disease [Crohn's disease,&#xD;
                  ulcerative colitis], idiopathic thrombocytopenic purpura, systemic lupus&#xD;
                  erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)&#xD;
&#xD;
               -  Clinical gout&#xD;
&#xD;
               -  Creatinine clearance less than or equal to 50 mL/min&#xD;
&#xD;
               -  any medical condition which may require use of chronic systemic steroids&#xD;
&#xD;
          -  Subject is or was a substance abuser, such as alcohol (80 g/day or more), methadone,&#xD;
             intravenous (IV), oral or inhaled drugs. To be considered for inclusion, the subject&#xD;
             must have abstained and agree to abstain from using any of the above for at least 6&#xD;
             months. Subjects treated with buprenorphine (Subutex) who have been stable for 6&#xD;
             months may be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2009</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf&#xD;
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The majority of subjects who discontinued due to treatment failure were withdrawn from the study as non-responders according to protocol requirements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PegIntron Plus Rebetol</title>
          <description>PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PegIntron Plus Rebetol</title>
          <description>PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.54" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</title>
        <description>Sustained virologic response is defined as a plasma HCV RNA level below Lower Level of Quantitation at 24 weeks post-treatment, which is &lt; 30 IU/mL in this study.</description>
        <time_frame>Up to 48 weeks of treatment plus 24 weeks follow up</time_frame>
        <population>The All Treated population included all subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron Plus Rebetol</title>
            <description>PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</title>
          <description>Sustained virologic response is defined as a plasma HCV RNA level below Lower Level of Quantitation at 24 weeks post-treatment, which is &lt; 30 IU/mL in this study.</description>
          <population>The All Treated population included all subjects who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PegIntron Plus REBETOL</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INTENTION TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>PSEUDODEMENTIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="86" subjects_affected="25" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to slow enrollment, an unplanned interim analysis was conducted: 75 of 93 (80.6%) subjects who had reached treatment Week 12 did not achieve early virologic response. Given the low likelihood of response, a decision was made to stop enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

